Literature DB >> 3122377

Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus.

G Gatti1, F Crema, G Attardo-Parrinello, P Fratino, F Aguzzi, E Perucca.   

Abstract

The serum protein binding of valproic acid (VPA) and phenytoin (PHT) was determined in spiked serum samples collected from 17 patients with insulin-dependent diabetes mellitus and 16 healthy control subjects. The free fraction of VPA was significantly greater in patients than in controls (7.6 +/- 1.6% vs. 6.2 +/- 1.2%, p less than 0.01); for PHT, free fraction values were similar in the two groups (8.2 +/- 1.1% vs. 8.4 +/- 1.2%). The free fraction of VPA in diabetic patients was positively correlated with free fatty acid (FFA) concentration (r = 0.79, p less than 0.01). No significant relationships could be found between free drug fraction and either serum albumin or glycosylated protein concentration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3122377     DOI: 10.1097/00007691-198712000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats.

Authors:  P B Inskeep; A E Reed; R A Ronfeld
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

Review 4.  The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.

Authors:  P R Gwilt; R R Nahhas; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

5.  Protein binding of digitoxin, valproate and phenytoin in sera from diabetics.

Authors:  J Doucet; J Fresel; G Hue; N Moore
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Plasma protein binding of lidocaine and warfarin in insulin-dependent and non-insulin-dependent diabetes mellitus.

Authors:  S O'Byrne; M G Barry; W C Collins; P O'Connor; M J Cullen; J Feely
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

Review 7.  Review: Glycation of human serum albumin.

Authors:  Jeanethe Anguizola; Ryan Matsuda; Omar S Barnaby; K S Hoy; Chunling Wa; Erin DeBolt; Michelle Koke; David S Hage
Journal:  Clin Chim Acta       Date:  2013-07-24       Impact factor: 3.786

8.  Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Chunling Wa; Ronald L Cerny; William A Clarke; David S Hage
Journal:  Clin Chim Acta       Date:  2007-06-23       Impact factor: 3.786

Review 9.  Drug administration in patients with diabetes mellitus. Safety considerations.

Authors:  R E Gilbert; M E Cooper; H Krum
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

10.  Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy.

Authors:  Alok S Tripathi; Papiya M Mazumder; Anil V Chandewar
Journal:  J Diabetes Metab Disord       Date:  2014-01-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.